Please login to the form below

Not currently logged in
Email:
Password:

Alder Biopharmaceuticals

This page shows the latest Alder Biopharmaceuticals news and features for those working in and with pharma, biotech and healthcare.

Novartis says migraine prevention drug clears phase III trial

Novartis says migraine prevention drug clears phase III trial

Novartis and Amgen are in a race withand Alder Biopharmaceuticals to bring the first CGRP-blocking drug to market.

Latest news

More from news
Approximately 1 fully matching, plus 6 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2018

    Licence. 217. Teva Pharmaceuticals/ Alder Biopharmaceuticals. Patents covering anti-calcitonin gene-related peptide (CGRP) antibodies and methods - eptinezumab (p3). † ... Teva/Alder Biopharmaceuticals patent settlement. We have featured Teva in Deal

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
3 Monkeys Zeno

3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...

Latest intelligence

Measures for measures
Why pharma’s marketing metrics must close the loop...
Where next in Alzheimer’s disease R&D?
How past failures and emerging biology are reshaping drug development...
Brain scan
Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...

Infographics